SynDevRx, Inc.

États‑Unis d’Amérique

 
Quantité totale PI 45
Rang # Quantité totale PI 30 775
Note d'activité PI 2,2/5.0    24
Rang # Activité PI 33 318
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

23 3
7 1
10 1
0
 
Dernier brevet 2024 - Metap2 inhibitors for the treatm...
Premier brevet 2011 - Polymer-conjugated metap2 inhibi...
Dernière marque 2023 - AMELIA
Première marque 2007 - SYNDEVRX

Industrie (Classification de Nice)

Derniers inventions, produits et services

2023 Invention Metap2 inhibitors for the treatment of prostate cancer. The present disclosure provides pharmaceu...
Invention Metap2 inhibitors for the treatment of pulmonary fibrosis. The present disclosure provides pharma...
P/S Providing information about clinical trials for pharmaceutical preparations Provision of medical ...
Invention Combinations comprising metap2 inhibitors for the treatment of cancer. The present disclosure pro...
Invention Biomarkers of metap2 inhibitors and applications thereof. The present disclosure relates to modi...
2022 Invention Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof. One aspect of the ...
Invention Treatment for tumors driven by metabolic dysfuction. The present disclosure relates to modified ...
Invention Metap2 inhibitors and methods of treating obesity. The present invention relates to modified or ...
2021 Invention Combinations of metap2 inhibitors and cd4/6 inhibitors for the treatment of cancer. The present ...
Invention Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer. The present ...
2020 Invention Treatment for tumors driven by metabolic dysfunction. The present disclosure relates to modified ...
Invention Metap2 inhibitors and methods of treating obesity. The present invention relates to modified or p...
2019 Invention Biomarkers of metap2 inhibitors and applications thereof. The present disclosure relates to small...
2018 Invention Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof. One aspect of the i...
Invention Fumagillol derivatives and polymorphs thereof. The present disclosure relates to salts and polymo...
2017 P/S Pharmaceutical preparations for the treatment of cancer and metabolic disorders, namely hyperinsu...
P/S Pharmaceutical preparations for the treatment of cancer and metabolic disorders.
P/S Pharmaceutical preparations for the treatment of cancer and metabolic disorders
Invention Treatment for tumors driven by metabolic dysfunction. The present disclosure provides methods and...
2014 Invention Optimized drug conjugates. The invention generally relates to optimized drug conjugates.
2011 Invention Optimized drug conjugates. Optimized drug conjugates, wherein the active moiety is modified and a...
2007 P/S [ Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharma...